Watches a curated tag library of brands, products, people, and cultural movements across public Reddit feeds. Flags a trend only when mention volume runs ≥ 2σ above its 14-day baseline on at least two corroborating sources, with the conversation persisting more than 24 hours. Trade ideas, not advice — size from your social-arb risk-capital bucket only.
Tags tracked
13
Entry window
0
Validated trends
0
Active theses
10
Last data
2026-05-26
Manual scan
Background jobs — start one, then keep working. The page refreshes when the job finishes.
Fires HTTP + Browser + Exit-evaluator in parallel. Total ≈ slowest (~6 min).
~360s
Polls the 12 curated RSS feeds. ~5s.
~10s
Reddit + Bluesky + GDELT + HN + Wikipedia + articles. ~3–4 min.
~240s
Google Trends + X + Threads + YouTube via Playwright. Requires a logged-in profile. ~5–6 min.
~360s
Re-evaluates open theses; closes mainstreamed/saturated ones. ~10s.
ATR-sized entry/stop/target with explicit invalidators
Crocs / Jibbitz
▲ LONG CROX
MEDIUM CONVICTION
Crocs / Jibbitz mentions are 125.0σ above their 0.0/day baseline across 2 corroborating sources, with mixed sentiment (0%). CROX benefits this trend — Direct brand mention proxy for Crocs Inc. Trade idea, not advice; size from your social-arb risk-capital bucket only.
Entry
$110.44
Stop
$102.60
Target
$126.13
R-mult
2.00R
ATR(14)
$3.92
Size
$14,026
Shares
127
Horizon
21d
Invalidators (4)
Mention z-score reverts below 1.0 on the dominant source (browser:google-trends) for two consecutive days.
Net sentiment flips negative (< −0.15) while mention volume stays elevated — the conversation has turned against CROX.
Mainstream-media coverage (CNBC, WSJ, Bloomberg) picks up the story — the information-imbalance window has closed.
Earnings or guidance release confirms the trend has already been digested — exit before the next print.
Dr. Martens (declining buzz)
▼ SHORT DOCS.L
MEDIUM CONVICTION
Dr. Martens (declining buzz) mentions are 63.0σ above their 0.0/day baseline across 2 corroborating sources, with mixed sentiment (0%). DOCS.L is at risk from this trend — Dr. Martens plc — falling brand mention coincides with US wholesale weakness. Trade idea, not advice; size from your social-arb risk-capital bucket only.
Entry
$69.60
Stop
$77.46
Target
$53.88
R-mult
2.00R
ATR(14)
$3.93
Size
$8,839
Shares
127
Horizon
21d
Invalidators (4)
Mention z-score reverts below 1.0 on the dominant source (browser:google-trends) for two consecutive days.
Net sentiment flips positive (> 0.15) while mentions stay elevated — the brand response is recovering.
Mainstream-media coverage (CNBC, WSJ, Bloomberg) picks up the story — the information-imbalance window has closed.
Earnings or guidance release confirms the trend has already been digested — exit before the next print.
Stanley Tumbler
▼ SHORT YETI
MEDIUM CONVICTION
Stanley Tumbler mentions are 47.0σ above their 0.0/day baseline across 2 corroborating sources, with mixed sentiment (19%). YETI is at risk from this trend — Stanley's viral Quencher cycle pulls share from YETI's Rambler line in the personal-drinkware category. Trade idea, not advice; size from your social-arb risk-capital bucket only.
Entry
$45.22
Stop
$49.93
Target
$35.79
R-mult
2.00R
ATR(14)
$2.36
Size
$9,587
Shares
212
Horizon
21d
Invalidators (4)
Mention z-score reverts below 1.0 on the dominant source (browser:google-trends) for two consecutive days.
Net sentiment flips positive (> 0.15) while mentions stay elevated — the brand response is recovering.
Mainstream-media coverage (CNBC, WSJ, Bloomberg) picks up the story — the information-imbalance window has closed.
Earnings or guidance release confirms the trend has already been digested — exit before the next print.
Labubu (Pop Mart)
▲ LONG PMRTY
MEDIUM CONVICTION
Labubu (Pop Mart) mentions are 34.0σ above their 0.0/day baseline across 3 corroborating sources, with mixed sentiment (-18%). PMRTY benefits this trend — Pop Mart ADR — Labubu is the flagship blind-box franchise. Trade idea, not advice; size from your social-arb risk-capital bucket only.
Entry
$19.03
Stop
$17.29
Target
$22.53
R-mult
2.00R
ATR(14)
$0.87
Size
$10,888
Shares
572
Horizon
21d
Invalidators (4)
Mention z-score reverts below 1.0 on the dominant source (reddit:r/popmart) for two consecutive days.
Net sentiment flips negative (< −0.15) while mention volume stays elevated — the conversation has turned against PMRTY.
Mainstream-media coverage (CNBC, WSJ, Bloomberg) picks up the story — the information-imbalance window has closed.
Earnings or guidance release confirms the trend has already been digested — exit before the next print.
Lululemon Align leggings mentions are 30.0σ above their 0.0/day baseline across 2 corroborating sources, with negative sentiment (-27%). LULU benefits this trend — Direct revenue driver — Align is LULU's largest single SKU family. Trade idea, not advice; size from your social-arb risk-capital bucket only.
Entry
$127.18
Stop
$119.47
Target
$142.61
R-mult
2.00R
ATR(14)
$3.86
Size
$16,406
Shares
129
Horizon
21d
Invalidators (4)
Mention z-score reverts below 1.0 on the dominant source (browser:google-trends) for two consecutive days.
Net sentiment flips negative (< −0.15) while mention volume stays elevated — the conversation has turned against LULU.
Mainstream-media coverage (CNBC, WSJ, Bloomberg) picks up the story — the information-imbalance window has closed.
Earnings or guidance release confirms the trend has already been digested — exit before the next print.
Lululemon Align leggings mentions are 30.0σ above their 0.0/day baseline across 2 corroborating sources, with negative sentiment (-27%). GAP is at risk from this trend — Athleta share-loss in the same price tier. Trade idea, not advice; size from your social-arb risk-capital bucket only.
Entry
$23.39
Stop
$25.19
Target
$19.78
R-mult
2.00R
ATR(14)
$0.90
Size
$12,958
Shares
554
Horizon
21d
Invalidators (4)
Mention z-score reverts below 1.0 on the dominant source (browser:google-trends) for two consecutive days.
Net sentiment flips positive (> 0.15) while mentions stay elevated — the brand response is recovering.
Mainstream-media coverage (CNBC, WSJ, Bloomberg) picks up the story — the information-imbalance window has closed.
Earnings or guidance release confirms the trend has already been digested — exit before the next print.
GLP-1 / Ozempic weight-loss mentions are -1.5σ above their 1288.0/day baseline across 3 corroborating sources, with mixed sentiment (0%). NVO benefits this trend — Novo Nordisk — Ozempic / Wegovy manufacturer. Trade idea, not advice; size from your social-arb risk-capital bucket only.
Entry
$44.96
Stop
$42.53
Target
$49.83
R-mult
2.00R
ATR(14)
$1.22
Size
$18,479
Shares
411
Horizon
21d
Invalidators (4)
Mention z-score reverts below 1.0 on the dominant source (browser:google-trends) for two consecutive days.
Net sentiment flips negative (< −0.15) while mention volume stays elevated — the conversation has turned against NVO.
Mainstream-media coverage (CNBC, WSJ, Bloomberg) picks up the story — the information-imbalance window has closed.
Earnings or guidance release confirms the trend has already been digested — exit before the next print.
GLP-1 / Ozempic weight-loss mentions are -1.5σ above their 1288.0/day baseline across 3 corroborating sources, with mixed sentiment (0%). LLY benefits this trend — Eli Lilly — Mounjaro / Zepbound manufacturer. Trade idea, not advice; size from your social-arb risk-capital bucket only.
Entry
$1,065
Stop
$1,007
Target
$1,181
R-mult
2.00R
ATR(14)
$28.91
Size
$18,105
Shares
17
Horizon
21d
Invalidators (4)
Mention z-score reverts below 1.0 on the dominant source (browser:google-trends) for two consecutive days.
Net sentiment flips negative (< −0.15) while mention volume stays elevated — the conversation has turned against LLY.
Mainstream-media coverage (CNBC, WSJ, Bloomberg) picks up the story — the information-imbalance window has closed.
Earnings or guidance release confirms the trend has already been digested — exit before the next print.
GLP-1 / Ozempic weight-loss mentions are -1.5σ above their 1288.0/day baseline across 3 corroborating sources, with mixed sentiment (0%). WW is at risk from this trend — WeightWatchers volume cannibalisation. Trade idea, not advice; size from your social-arb risk-capital bucket only.
Entry
$12.79
Stop
$15.67
Target
$7.03
R-mult
2.00R
ATR(14)
$1.44
Size
$4,438
Shares
347
Horizon
21d
Invalidators (4)
Mention z-score reverts below 1.0 on the dominant source (browser:google-trends) for two consecutive days.
Net sentiment flips positive (> 0.15) while mentions stay elevated — the brand response is recovering.
Mainstream-media coverage (CNBC, WSJ, Bloomberg) picks up the story — the information-imbalance window has closed.
Earnings or guidance release confirms the trend has already been digested — exit before the next print.
GLP-1 / Ozempic weight-loss mentions are -1.5σ above their 1288.0/day baseline across 3 corroborating sources, with mixed sentiment (0%). PEP is at risk from this trend — Snack-volume drag from appetite suppression. Trade idea, not advice; size from your social-arb risk-capital bucket only.
Entry
$150.57
Stop
$156.76
Target
$138.18
R-mult
2.00R
ATR(14)
$3.10
Size
$24,242
Shares
161
Horizon
21d
Invalidators (4)
Mention z-score reverts below 1.0 on the dominant source (browser:google-trends) for two consecutive days.
Net sentiment flips positive (> 0.15) while mentions stay elevated — the brand response is recovering.
Mainstream-media coverage (CNBC, WSJ, Bloomberg) picks up the story — the information-imbalance window has closed.
Earnings or guidance release confirms the trend has already been digested — exit before the next print.